Atorvaliq has 34 known drug interactions based on U.S. FDA drug labeling data. Of these, 4 are contraindicated combinations that should be avoided entirely. 9 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyclosporine, Gemfibrozil, Glecaprevir And Pibrentasvir. Patients taking Atorvaliq should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 34
- Contraindicated
- 4
- Major
- 9
- Moderate
- 3
Contraindicated (4)
- Atorvaliq + Cyclosporine— Significantly increases atorvastatin plasma levels and risk of myopathy and rhabdomyolysis. Concomitant use is not recom…
- Atorvaliq + Gemfibrozil— Increases risk of myopathy and rhabdomyolysis when used with ATORVALIQ. Concomitant use is not recommended.
- Atorvaliq + Glecaprevir And Pibrentasvir— Significantly increases atorvastatin plasma levels and risk of myopathy and rhabdomyolysis. Concomitant use is not recom…
- Atorvaliq + Tipranavir— Significantly increases atorvastatin plasma levels and risk of myopathy and rhabdomyolysis. Concomitant use is not recom…
Major (9)
- Atorvaliq + Darunavir— Significantly increases atorvastatin plasma levels. Do not exceed ATORVALIQ 20 mg.
- Atorvaliq + Elbasvir And Grazoprevir— Significantly increases atorvastatin plasma levels. Do not exceed ATORVALIQ 20 mg.
- Atorvaliq + Fosamprenavir— Significantly increases atorvastatin plasma levels. Do not exceed ATORVALIQ 20 mg.
- Atorvaliq + Ledipasvir And Sofosbuvir— Cases of myopathy and rhabdomyolysis reported. Consider risk/benefit of concomitant use.
- Atorvaliq + Letermovir— Significantly increases atorvastatin plasma levels. Do not exceed ATORVALIQ 20 mg.
- Atorvaliq + Lopinavir And Ritonavir— Significantly increases atorvastatin plasma levels. Consider risk/benefit of concomitant use.
- Atorvaliq + Nelfinavir— Significantly increases atorvastatin plasma levels. Do not exceed ATORVALIQ 40 mg.
- Atorvaliq + Saquinavir— Significantly increases atorvastatin plasma levels. Do not exceed ATORVALIQ 20 mg.
- Atorvaliq + Simeprevir— Significantly increases atorvastatin plasma levels. Consider risk/benefit of concomitant use.
Moderate (3)
- Atorvaliq + Digoxin— May increase digoxin plasma levels; monitor patients appropriately.
- Atorvaliq + Oral Contraceptives— May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contracep…
- Atorvaliq + Rifampin— May reduce atorvastatin plasma concentrations. Administer simultaneously with ATORVALIQ.